A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users

Health Psychol. 2003 Mar;22(2):223-8.


This study randomized 90 HIV-seropositive, methadone-maintained injection drug users (IDUs) to an HIV Harm Reduction Program (HHRP+) or to an active control that included harm reduction components recommended by the National AIDS Demonstration Research Project. The treatment phase lasted 6 months, with follow-ups at 6 and 9 months after treatment entry. Patients in both treatments showed reductions in risk behaviors. However, patients assigned to HHRP+ were less likely to use illicit opiates and were more likely to adhere to antiretroviral medications during treatment; at follow-up, they had lower addiction severity scores and were less likely to have engaged in high risk behavior. Findings suggest that enhancing methadone maintenance with an intervention targeting HIV-seropositive IDUs increases both harm reduction and health promotion behaviors.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / prevention & control*
  • Adult
  • Female
  • Follow-Up Studies
  • HIV Seropositivity / complications*
  • HIV Seropositivity / epidemiology*
  • Health Promotion*
  • Humans
  • Male
  • Manuals as Topic*
  • Risk Factors
  • Risk-Taking
  • Substance Abuse, Intravenous / complications*
  • Substance Abuse, Intravenous / psychology